Sensitivity of C6 Glioma Cells Carrying the Human Poliovirus Receptor to Oncolytic Polioviruses
- Authors: Sosnovtseva A.O.1,2, Lipatova A.V.2, Grinenko N.F.3, Baklaushev V.P.1, Chumakov P.M.2, Chekhonin V.P.1,3
-
Affiliations:
- Department of Medical Nanobiotechnologies, Medical and Biological Faculty, N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation
- Laboratory of Cell Proliferation, V. A. Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
- Department of Basic and Applied Neurobiology, V. P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation
- Issue: Vol 161, No 6 (2016)
- Pages: 821-825
- Section: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/237814
- DOI: https://doi.org/10.1007/s10517-016-3520-1
- ID: 237814
Cite item
Abstract
A humanized line of rat C6 glioma cells expressing human poliovirus receptor was obtained and tested for the sensitivity to oncolytic effects of vaccine strains of type 1, 2, and 3 polioviruses. Presentation of the poliovirus receptor on the surface of C6 glioma cells was shown to be a necessary condition for the interaction of cells with polioviruses, but insufficient for complete poliovirus oncolysis.
About the authors
A. O. Sosnovtseva
Department of Medical Nanobiotechnologies, Medical and Biological Faculty, N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation; Laboratory of Cell Proliferation, V. A. Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
Author for correspondence.
Email: aososnovtceva@gmail.com
Russian Federation, Moscow; Moscow
A. V. Lipatova
Laboratory of Cell Proliferation, V. A. Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
Email: aososnovtceva@gmail.com
Russian Federation, Moscow
N. F. Grinenko
Department of Basic and Applied Neurobiology, V. P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation
Email: aososnovtceva@gmail.com
Russian Federation, Moscow
V. P. Baklaushev
Department of Medical Nanobiotechnologies, Medical and Biological Faculty, N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation
Email: aososnovtceva@gmail.com
Russian Federation, Moscow
P. M. Chumakov
Laboratory of Cell Proliferation, V. A. Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
Email: aososnovtceva@gmail.com
Russian Federation, Moscow
V. P. Chekhonin
Department of Medical Nanobiotechnologies, Medical and Biological Faculty, N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation; Department of Basic and Applied Neurobiology, V. P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation
Email: aososnovtceva@gmail.com
Russian Federation, Moscow; Moscow